(Q41329621)

29 September 2017

1 reference

title

Osteoporosis. Current pharmacologic options for prevention and treatment (English)

1 reference

29 September 2017

0 references

D W Isenbarger

1

1 reference

29 September 2017

B L Chapin

series ordinal

2

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

29 September 2017

published in

Postgraduate Medicine

1 reference

29 September 2017

volume

101

1 reference

29 September 2017

issue

1

1 reference

29 September 2017

page(s)

129-32, 136-7, 141-2

1 reference

Treatment options for osteoporosis

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

The prevention and treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Estrogen and coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Hormone therapy to prevent disease and prolong life in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Hormone replacement therapy: compliance and cost after screening for osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Calcitonin for prevention of postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.01.145

21 January 2018

Identifiers

DOI

10.3810/PGM.1997.01.145

1 reference

29 September 2017

1 reference